Dexcom said it will present new clinical and real-world evidence on its continuous glucose monitoring (CGM) technology at the Advanced Technologies and Treatments for Diabetes Conference in Barcelona, March 11–14, 2026. The company cited a multi-center U.S. primary care registry analysis reporting that after one year of Dexcom G7 use, people with type 2 diabetes not using insulin had improvements in HbA1c and weight management. Dexcom also referenced claims-data findings that CGM initiation was associated with fewer diabetic ketoacidosis-related hospitalizations and emergency room visits in children and adults with type 1 diabetes. In addition, it highlighted a prospective multi-center feasibility study reporting that Dexcom Smart Basal was safe and effective for people with type 2 diabetes starting or optimizing basal insulin therapy. Dexcom said its symposium at the meeting will cover upcoming product features across Dexcom G7 and Dexcom G7 15 Day, as well as Dexcom ONE+, Stelo, and Clarity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260310854672) on March 11, 2026, and is solely responsible for the information contained therein.